Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy

Alessia Cimadamore, Antonio Lopez-Beltran, Francesco Massari, Matteo Santoni, Roberta Mazzucchelli, Marina Scarpelli, Andrea B. Galosi, Liang Cheng, Rodolfo Montironi

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)75-80
Number of pages6
JournalFuture Oncology
Volume16
Issue number5
DOIs
StatePublished - Jan 1 2020

Keywords

  • BRCA1
  • BRCA2
  • defective DNA repair
  • immunotherapy
  • PARP inhibitors
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cimadamore, A., Lopez-Beltran, A., Massari, F., Santoni, M., Mazzucchelli, R., Scarpelli, M., Galosi, A. B., Cheng, L., & Montironi, R. (2020). Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy. Future Oncology, 16(5), 75-80. https://doi.org/10.2217/fon-2019-0745